Literature DB >> 22954016

Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study.

Leon G Epstein1, Shlomo Shinnar, Dale C Hesdorffer, Douglas R Nordli, Aaliyah Hamidullah, Emma K T Benn, John M Pellock, L Matthew Frank, Darrell V Lewis, Solomon L Moshe, Ruth C Shinnar, Shumei Sun.   

Abstract

PURPOSE: In a prospective study, Consequences of Prolonged Febrile Seizures in Childhood (FEBSTAT), we determined the frequency of human herpesvirus (HHV)-6 and HHV-7 infection as a cause of febrile status epilepticus (FSE).
METHODS: Children ages 1 month to 5 years presenting with FSE were enrolled within 72 h and received a comprehensive assessment including specimens for HHV-6 and HHV-7. The presence of HHV-6A, HHV-6B, or HHV-7 DNA and RNA (amplified across a spliced junction) determined using quantitative polymerase chain reaction (qPCR) at baseline indicated viremia. Antibody titers to HHV-6 and HHV-7 were used in conjunction with the PCR results to distinguish primary infection from reactivated or prior infection. KEY
FINDINGS: Of 199 children evaluated, HHV-6 or HHV-7 status could be determined in 169 (84.9%). HHV-6B viremia at baseline was found in 54 children (32.0%), including 38 with primary infection and 16 with reactivated infection. No HHV-6A infections were identified. HHV-7 viremia at baseline was observed in 12 children (7.1%), including eight with primary infection and four with reactivated infection. Two subjects had HHV-6/HHV-7 primary coinfection at baseline. There were no differences in age, characteristics of illness or fever, seizure phenomenology or the proportion of acute EEG or imaging abnormalities in children presenting with FSE with or without HHV infection. SIGNIFICANCE: HHV-6B infection is commonly associated with FSE. HHV-7 infection is less frequently associated with FSE. Together, they account for one third of FSE, a condition associated with an increased risk of both hippocampal injury and subsequent temporal lobe epilepsy. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2012        PMID: 22954016      PMCID: PMC3442944          DOI: 10.1111/j.1528-1167.2012.03542.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  46 in total

1.  Febrile Seizures and Mesial Temporal Sclerosis.

Authors:  Shlomo Shinnar
Journal:  Epilepsy Curr       Date:  2003-07       Impact factor: 7.500

2.  Hippocampal MRI signal hyperintensity after febrile status epilepticus is predictive of subsequent mesial temporal sclerosis.

Authors:  James M Provenzale; Daniel P Barboriak; Kevan VanLandingham; James MacFall; David Delong; Darrell V Lewis
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

3.  Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology.

Authors:  David Boutolleau; Caroline Duros; Pascale Bonnafous; Delphine Caïola; Alexandre Karras; Nathalie De Castro; Marie Ouachée; Philippe Narcy; Marie Gueudin; Henri Agut; Agnès Gautheret-Dejean
Journal:  J Clin Virol       Date:  2005-09-23       Impact factor: 3.168

4.  Variant-specific tropism of human herpesvirus 6 in human astrocytes.

Authors:  Donatella Donati; Elena Martinelli; Riccardo Cassiani-Ingoni; Jenny Ahlqvist; Jean Hou; Eugene O Major; Steve Jacobson
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 5.  Do prolonged febrile seizures produce medial temporal sclerosis? Hypotheses, MRI evidence and unanswered questions.

Authors:  Darrell V Lewis; Daniel P Barboriak; James R MacFall; James M Provenzale; Teresa V Mitchell; Kevan E VanLandingham
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

6.  Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6.

Authors:  Caroline Breese Hall; Mary T Caserta; Kenneth C Schnabel; Michael P McDermott; Geraldine K Lofthus; Jennifer A Carnahan; Lynne M Gilbert; Stephen Dewhurst
Journal:  J Infect Dis       Date:  2006-03-06       Impact factor: 5.226

7.  Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections.

Authors:  D Donati; N Akhyani; A Fogdell-Hahn; C Cermelli; R Cassiani-Ingoni; A Vortmeyer; J D Heiss; P Cogen; W D Gaillard; S Sato; W H Theodore; S Jacobson
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

8.  Status epilepticus in childhood: a retrospective study of initial convulsive status and subsequent epilepsies.

Authors:  T Fujiwara; S Ishida; M Miyakoshi; N Sakuma; S Moriyama; T Morikawa; M Seino; T Wada
Journal:  Folia Psychiatr Neurol Jpn       Date:  1979

9.  An epidemiological study of children with status epilepticus in Okayama, Japan.

Authors:  Itsuko Nishiyama; Yoko Ohtsuka; Toshihide Tsuda; Hideo Inoue; Taiji Kunitomi; Hiroshi Shiraga; Takafumi Kimura; Kiyoshi Fujimoto
Journal:  Epilepsia       Date:  2007-04-18       Impact factor: 5.864

10.  Identification of human herpesvirus-6 as a causal agent for exanthem subitum.

Authors:  K Yamanishi; T Okuno; K Shiraki; M Takahashi; T Kondo; Y Asano; T Kurata
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

View more
  43 in total

1.  Early developmental outcomes of children with congenital HHV-6 infection.

Authors:  Mary T Caserta; Caroline B Hall; Richard L Canfield; Philip Davidson; Gerry Lofthus; Kenneth Schnabel; Jennifer Carnahan; Lynne Shelley; Hongyue Wang
Journal:  Pediatrics       Date:  2014-11-03       Impact factor: 7.124

Review 2.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

3.  Findings from the FEBSTAT Study: Can Observations After a Provoked Seizure Occurrence Have Broad Implications for Epileptogenesis?

Authors:  Cynthia Harden
Journal:  Epilepsy Curr       Date:  2013-05       Impact factor: 7.500

4.  T2 relaxation time post febrile status epilepticus predicts cognitive outcome.

Authors:  Jeremy M Barry; ManKin Choy; Celine Dube; Ashlee Robbins; Andre Obenaus; Pierre Pascal Lenck-Santini; Rod C Scott; Tallie Z Baram; Gregory L Holmes
Journal:  Exp Neurol       Date:  2015-05-01       Impact factor: 5.330

5.  The Brief Case: Inherited Chromosomally Integrated Human Herpesvirus 6 (HHV-6) in the Age of Multiplex HHV-6 Testing.

Authors:  Alexander L Greninger; Samia N Naccache; Pia Pannaraj; Keith R Jerome; Jennifer Dien Bard; Jeanne W Ruderman
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

6.  Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury.

Authors:  William B Gallentine; Shlomo Shinnar; Dale C Hesdorffer; Leon Epstein; Douglas R Nordli; Darrell V Lewis; L Matthew Frank; Syndi Seinfeld; Ruth C Shinnar; Karen Cornett; Binyi Liu; Solomon L Moshé; Shumei Sun
Journal:  Epilepsia       Date:  2017-04-27       Impact factor: 5.864

7.  Turning up the heat on the impact of febrile status epilepticus.

Authors:  Eric Kossoff
Journal:  Epilepsy Curr       Date:  2013-01       Impact factor: 7.500

8.  A Lesson from "The Brodie Ultimatum": The Locus of Control for Epilepsy is Outside the Therapeutic Alliance.

Authors:  Cynthia Harden
Journal:  Epilepsy Curr       Date:  2013-01       Impact factor: 7.500

Review 9.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

10.  Design and phenomenology of the FEBSTAT study.

Authors:  Dale C Hesdorffer; Shlomo Shinnar; Darrell V Lewis; Solomon L Moshé; Douglas R Nordli; John M Pellock; James MacFall; Ruth C Shinnar; David Masur; L Matthew Frank; Leon G Epstein; Claire Litherland; Syndi Seinfeld; Jacqueline A Bello; Stephen Chan; Emilia Bagiella; Shumei Sun
Journal:  Epilepsia       Date:  2012-06-28       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.